Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Healthcare Biotechnology
Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Oncolytics Biotech Inc > Biden Vows to Fund Biotech to Fight Cancer on 60th "Moonshot
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(5716)
•••
Comment by Noteableon Sep 15, 2022 7:16pm
186 Views
Post# 34965723

RE:RE:RE:RE:RE:RE:Biden Vows to Fund Biotech to Fight Cancer on 60th "Moonshot

RE:RE:RE:RE:RE:RE:Biden Vows to Fund Biotech to Fight Cancer on 60th "MoonshotSeptember 15, 2022 -  Biden’s “Cancer Moonshot” Brings Biotech Focus Back to U.S.

[ONCY's US head office is in San Diego California, and ONCY is registered in Delaware as a US company.

And any Big Pharma company acquiring ONCY has the benefit of Biden's "Cancer Moonshot" funding because of ONCY's precison medicine focus and the advanced manufacturing component that ONCY presents as an immuno-oncology agent with a predictive diagnoticc biomarker]

Biden acknowledged the inequities in diagnosing and treating cancer within the U.S., with vast differences in outcomes based on an individual’s race, sexual orientation, gender identity, disability, and where they live. He hopes to elevate the entire system in a push to cure cancer by supporting research, biotechnology, biomedicine, and more in the U.S., and laid out the framework for government support in the sector.

And industry was quick to applaud. Pfizer CEO Albert Bourla tweeted, “Excited to see @POTUS inspiring action through the #CancerMoonshot Initiative.”

https://www.etftrends.com/model-portfolio-channel/bidens-cancer-moonshot-brings-biotech-focus-back-to-u-s/


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities